Print this page
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
Protocol: 012313Principal Investigator:
- Amer Assal MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Multiple Myeloma -
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
Protocol: 112308Principal Investigator:
- Meenakshi Goyal-Khemka (Rutgers University)
Applicable Disease Sites: Leukemia, other -
A Phase 3 Trial of Fianlimab (Anti-Lag-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-Risk Melanoma.
Protocol: 092204Principal Investigator:
- Adam Berger (Rutgers University)
Applicable Disease Sites: Melanoma, Skin -
Expanded Access Protocol: Umbilical Cord Blood Infusions for Children with Brain Injuries
Protocol: 112207Principal Investigator:
- Archana Sharma DO (Rutgers University)
Applicable Disease Sites: Other -
A Phase 2 Study of Dabrafenib with Trametinib after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG).
Protocol: 112302Principal Investigator:
- Teena Bhatla (Newark Beth Israel Medical Center)
Applicable Disease Sites: Brain and Nervous System -
An Open-label, Expanded Access Protocol for Pediatric Patients with Sickle Cell Disease Who Have No Alternative Treatment Options.
Protocol: 112304Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Any Site